Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)
Latest Information Update: 16 May 2025
At a glance
- Drugs Cobolimab (Primary) ; Dostarlimab (Primary)
- Indications Hodgkin's disease; Malignant melanoma; Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms POPSTAR
- Sponsors GSK
Most Recent Events
- 27 Feb 2025 Planned End Date changed from 12 Nov 2030 to 2 Jan 2032.
- 27 Feb 2025 Planned primary completion date changed from 17 Aug 2028 to 5 Oct 2029.
- 27 Feb 2025 Planned initiation date changed from 31 Dec 2024 to 28 Feb 2025.